Any current/future capex/capital investment/strategic investment?

Ami Organics has approved a 16-megawatt captive solar power plant project with a CAPEX of approximately Rs. 65-70 crores; installation is expected to complete by the end of the financial year. Additionally, a 5-megawatt solar power plant is already in progress, which will help offset electricity expenses once operational. CAPEX for H1 FY24 was Rs. 105 crores, with another Rs. 100-110 crores expected by year-end. The Ankleshwar facility, acquired from Gujarat Organics with an investment of around Rs. 190 crores, will be operational by mid-December 2023, ramping up in Q4 FY24 to contribute to re

Future growth expectations in sales/revenue/volumes?

FY24 revenue growth target revised downward to 18%-22% from earlier 22%-25%, mainly due to pricing erosion despite volume growth of 20%-25%. Volume growth expected to remain strong; value/realization affected by pricing pressures. Muted performance expected in FY24 due to delayed product launches and acquisition/integration of Baba Fine Chemicals; FY25 anticipated to be better than both FY23 and FY24. Baba Fine Chemicals integration year in FY24; exponential growth targeted in coming years with aim for Rs. 200-250 crore topline in 4-5 years. Full utilization of Ankleshwar facility capa

Future growth expectations in earnings/operating earnings/profits/EPS?

FY24 is expected to be a muted year in terms of growth, with some deferred revenue impacting quarterly performance. FY25 is projected to be better than both FY23 and FY24, with significant ramp-up in operations, especially from new contracts and Ankleshwar facility. Company targets operating the Ankleshwar facility at full capacity by FY27. Volume growth is expected to continue strongly at 20%-25%, though price erosion has moderated top-line growth guidance from 22-25% to 18-22% for FY24. EBITDA margin guidance is around 6%-7% improvement on a broader level; margin recovery expected starting Q

Current/ Expected Orderbook/ Pending Orders?

Ami Organics has a strong order book for H2 FY24, signaling expected robust performance in the coming quarters (Page 6). The company has ongoing contracts including a Fermion contract with supply of 3 intermediates; one intermediate supply has started, and validations for the remaining two intermediates will begin in the 2nd half of December, targeting commercial supply in H2 FY25 (Page 13). Ankleshwar facility has 33% capacity allocated to Fermion, which is fully booked, with remaining capacity available to fulfill future demand until FY27 (Page 12). The company is reducing inventory for dome

Acutaas Chemicals LtdQ2 FY24Pharmaceuticals & Biotechnology

Acutaas Chemicals Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,196P/E: 69.4Market Cap: ₹26.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

FY24 revenue growth target revised downward to 18%-22% from earlier 22%-25%, mainly due to pricing erosion despite volume growth of 20%-25%.
Volume growth expected to remain strong; value/realization affected by pricing pressures.
Muted performance expected in FY24 due to delayed product launches and acquisition/integration of Baba Fine Chemicals; FY25 anticipated to be better than both FY23 and FY24.
Baba Fine Chemicals integration year in FY24; exponential growth targeted in coming years with aim for Rs. 200-250 crore topline in 4-5 years.
Full utilization of Ankleshwar facility capacity targeted by FY27 with ongoing pipeline discussions.
Specialty chemicals segment targeting to achieve 2.5x growth over next couple of years.
New product launches (e.g., UV absorber, electrolyte additives) expected to contribute revenue from Q3 FY24 onwards.
Fermion contract revenues expected to ramp up fully by H2 FY25.

Margin guidance

Category 3

FY24 is expected to be a muted year in terms of growth, with some deferred revenue impacting quarterly performance.
FY25 is projected to be better than both FY23 and FY24, with significant ramp-up in operations, especially from new contracts and Ankleshwar facility.
Company targets operating the Ankleshwar facility at full capacity by FY27.
Volume growth is expected to continue strongly at 20%-25%, though price erosion has moderated top-line growth guidance from 22-25% to 18-22% for FY24.
EBITDA margin guidance is around 6%-7% improvement on a broader level; margin recovery expected starting Q3 FY24 as raw material prices stabilize.
Baba Fine Chem subsidiary expected to scale up post consolidation in FY24, targeting Rs. 200-250 crore revenue in 4-5 years.
New product launches and contract ramp-ups (e.g., Fermion) will contribute to improved profitability from FY25 onward.

See what Acutaas Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

- There is no explicit mention of any current or planned new fundraising through debt or equity in the Q2 FY24 earnings call transcript. - The company has ongoing CAPEX plans, including a 16-megawatt solar power plant project with a CAPEX of around Rs. 65-70 crores and Ankleshwar facility expansion, with Rs. 100-110 crores expected by year-end. - No specific discussions or announcements about raising funds via debt or equity were made during the call. - Management focused on operational updates, acquisitions (Baba Fine Chem), pricing pressures, and growth prospects without addressing new capital raising. - For any missed or follow-up queries, management suggested contacting their IR advisor (E&Y), indicating no immediate public fundraising announcements. Hence, based on the available transcript till November 9, 2023, there is no current or near-future fundraising indicated.

Order book

Yes

Ami Organics has a strong order book for H2 FY24, signaling expected robust performance in the coming quarters (Page 6).
The company has ongoing contracts including a Fermion contract with supply of 3 intermediates; one intermediate supply has started, and validations for the remaining two intermediates will begin in the 2nd half of December, targeting commercial supply in H2 FY25 (Page 13).
Ankleshwar facility has 33% capacity allocated to Fermion, which is fully booked, with remaining capacity available to fulfill future demand until FY27 (Page 12).
The company is reducing inventory for domestic requirements post pricing pressure and expects recovery in positioning and margins from here onwards (Page 6).
New validations and product launches are anticipated, supporting the order pipeline and revenue visibility.

See what Acutaas Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Ami Organics has approved a 16-megawatt captive solar power plant project with a CAPEX of approximately Rs. 65-70 crores; installation is expected to complete by the end of the financial year.
Additionally, a 5-megawatt solar power plant is already in progress, which will help offset electricity expenses once operational.
CAPEX for H1 FY24 was Rs. 105 crores, with another Rs. 100-110 crores expected by year-end.
The Ankleshwar facility, acquired from Gujarat Organics with an investment of around Rs. 190 crores, will be operational by mid-December 2023, ramping up in Q4 FY24 to contribute to revenues.
The Ankleshwar site's capacity includes 33% allocated to the Fermion contract (fully booked) with 66% capacity free for future demand till FY27.
Ongoing focus on expanding strategic partnerships and commercial supplies—e.g., the Fermion contract with plans to start supplying two more intermediates commercially in H2 FY25.

Track Acutaas Chemicals Ltd — get its next earnings analysis in your feed

How does Acutaas Chemicals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAcutaas Chemicals Ltd

Rev 3Mar 3

See where Acutaas Chemicals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Acutaas Chemicals Ltd rank in Pharmaceuticals & Biotechnology?

Compare Acutaas Chemicals Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Acutaas Chemicals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Acutaas Chemicals Ltd Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Acutaas Chemicals Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Acutaas Chemicals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season